New weapon against tough lymphoma: re-engineered immune cells target cancer protein
Disease control
Recruiting now
This early-stage study is testing the safety and best dose of a new type of CAR T-cell therapy for adults with B-cell Non-Hodgkin's Lymphoma that has come back or stopped responding to standard treatments. Doctors take a patient's own immune cells (T cells), modify them in a lab …
Phase: PHASE1 • Sponsor: PeproMene Bio, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC